| MORPHEE : Mechanisms of Cell Death Induced by Extracorporeal Photochemotherapy (NCT05333367) | Centre Hospitalier Universitaire de Besancon | 2022-04-15 |
| Triamcinolone Acetonide Injections in Primary Cutaneous Lymphoma Plaques With a Novel Needle-free Drug-delivery System. (NCT05106192) | Case Comprehensive Cancer Center | 2022-04-01 |
| A Study of Bexarotene Combined With Radiotherapy in People With Mycosis Fungoides (NCT05296304) | Memorial Sloan Kettering Cancer Center | 2022-03-16 |
| A Phase I Trial of SIM1811-03 in Subjects With Advanced Tumors (NCT05781386) | Jiangsu Simcere Biologics Co., Ltd | 2022-03-06 |
| TOtal Skin Electron Beam Therapy (Low-dose) for Tumor Clone Eradication in Early-stage Mycosis Fungoides (NCT05205902) | Assistance Publique - Hôpitaux de Paris | 2022-02-01 |
| A Phase 1, Open-label Study of the Absorption, Metabolism, Excretion of [14C]-Resminostat (NCT04955340) | 4SC AG | 2021-10-12 |
| Photopheresis in Early-stage Mycosis Fungoides (NCT05680558) | Columbia University | 2021-05-08 |
| Romidepsin, CC-486 (5-azacitidine), Dexamethasone, and Lenalidomide (RAdR) for Relapsed/Refractory T-cell Malignancies (NCT04447027) | National Cancer Institute (NCI) | 2020-12-17 |
| A Pilot of a Microdevice For In Situ Candidate Drug Screening in Cutaneous Lesions of T-Cell Lymphoma (NCT04045470) | Dana-Farber Cancer Institute | 2019-12-11 |
| Sintilimab Plus Chidamide in the Treatment of Relapsed and Refractory Cutaneous T-cell Lymphoma: a Multicenter Phase II Study (NCT04296786) | Peking Union Medical College Hospital | 2019-11-01 |
| Post-authorization Safety Study of Allogeneic Hematopoietic Stem Cell Transplantation in Patients Treated With Mogamulizumab (NCT04014374) | Kyowa Kirin, Inc. | 2019-09-10 |
| Study Evaluating GZ17-6.02 in Patients With Advanced Solid Tumors or in Combination With Capecitabine in Metastatic Hormone Receptor Positive Breast Cancer (NCT03775525) | Genzada Pharmaceuticals USA, Inc. | 2019-03-01 |
| Characterization of the Microbiome in Cutaneous T Cell Lymphoma (NCT03932279) | Northwestern University | 2019-01-30 |
| A Trial Assessing the Effect of Pembrolizumab Combined with Radiotherapy in Patients with Relapsed, Refractory, Specified Stages of Cutaneous T-cell Lymphoma (CTCL) Mycosis Fungoides (MF)/Sezary Syndrome (SS) (NCT03385226) | University College, London | 2019-01-15 |
| Study of CAR-T Cells Expressing CD30 and CCR4 for r/r CD30+ HL and CTCL (NCT03602157) | UNC Lineberger Comprehensive Cancer Center | 2018-10-29 |
| Study of BGB-A317 in Participants With Relapsed or Refractory Mature T- and NK-cell Neoplasms (NCT03493451) | BeiGene | 2018-04-13 |
| Radiation Therapy Plus Durvalumab for Tumor-Stage Cutaneous T-Cell Lymphoma (NCT03235869) | University of Michigan Rogel Cancer Center | 2018-03-01 |
| Doxycycline for the Treatment of Cutaneous T-Cell Lymphoma (NCT02341209) | Rochester General Hospital | 2018-02-06 |
| A Safety, Efficacy and Pharmacokinetics Study of CD11301 for the Treatment of Cutaneous T-Cell Lymphoma (CTCL) (NCT03292406) | Galderma R&D | 2017-12-19 |
| Mechlorethamine Induced Contact Dermatitis Avoidance Study (NCT03380026) | Rochester Skin Lymphoma Medical Group, PLLC | 2017-12-13 |
| Romidepsin Maintenance After Allogeneic Stem Cell Transplantation (NCT02512497) | Ohio State University Comprehensive Cancer Center | 2017-12-08 |
| A Study of Tremelimumab and IV Durvalumab Plus Poly-ICLC in Subjects With Biopsy-accessible Cancers (NCT02643303) | Ludwig Institute for Cancer Research | 2016-12-28 |
| Low Dose Total Skin Electron Beam Treatment (TSEBT) Followed by Maintenance Valchlor for Patients With Mycosis Fungoides (NCT02881749) | Thomas Jefferson University | 2016-09-01 |
| Study of Tinostamustine, First-in-Class Alkylating HDACi Fusion Molecule, in Relapsed/Refractory Hematologic Malignancies (NCT02576496) | Mundipharma Research Limited | 2016-04-14 |
| Study of E7777 in Patients With Relapsed or Refractory Peripheral T-cell Lymphoma and Cutaneous T-cell Lymphoma (NCT02676778) | Eisai Co., Ltd. | 2016-03-28 |
| Micro Needle Array-Doxorubicin (MNA-D) in Patients With Cutaneous T-cell Lymphoma (CTCL) (NCT02192021) | Falo, Louis, MD | 2016-03-09 |
| FLASH [Fluorescent Light Activated Synthetic Hypericin] Clinical Study: Topical SGX301 (Synthetic Hypericin) for the Treatment of Cutaneous T-Cell Lymphoma (Mycosis Fungoides) (NCT02448381) | Soligenix | 2015-12-01 |
| Early Diagnosis of Mycosis Fungoides (NCT02539472) | Assistance Publique - Hôpitaux de Paris | 2015-11-01 |
| Study of IPH4102 in Patients With Relapsed/Refractory Cutaneous T-cell Lymphomas (CTCL) (NCT02593045) | Innate Pharma | 2015-10-01 |
| Study on Therapy With Dimethylfumarate (DMF) in Patients With Cutaneous T Cell Lymphoma (CTCL) (NCT02546440) | Universitätsmedizin Mannheim | 2015-09-01 |
| Long-term Use of Romidepsin in Patients With CTCL (NCT02296398) | Northwestern University | 2015-01-01 |
| Poly ICLC, Radiation, and Romidepsin for Advanced Cutaneous T Cell Lymphoma (NCT02061449) | NYU Langone Health | 2014-03-01 |
| Helical Irradiation of Total Skin (HITS) for Cutaneous Lymphoma (NCT02039895) | Far Eastern Memorial Hospital | 2014-01-01 |
| Trial of Curcumin in Cutaneous T-cell Lymphoma Patients (NCT00969085) | M.D. Anderson Cancer Center | 2012-11-01 |
| Study of KW-0761 Versus Vorinostat in Relapsed/Refractory CTCL (NCT01728805) | Kyowa Kirin, Inc. | 2012-11-01 |
| A Phase 3 Trial of Brentuximab Vedotin(SGN-35) Versus Physician's Choice (Methotrexate or Bexarotene) in Participants With CD30-Positive Cutaneous T-Cell Lymphoma (ALCANZA Study) (NCT01578499) | Millennium Pharmaceuticals, Inc. | 2012-06-11 |
| Everolimus in Treating Cutaneous T-cell Lymphoma (NCT01637090) | Adam Lerner | 2012-06-01 |
| STAT3 in T Cells: At The Crossroads of Inflammation and Cancer (NCT01663571) | NYU Langone Health | 2012-05-01 |
| Topical Resiquimod for the Treatment of Early Stage Cutaneous T Cell Lymphoma (CTCL) (NCT01676831) | Abramson Cancer Center at Penn Medicine | 2012-02-01 |
| Carbohydrate Metabolism Disorder Frequency in Hypertriglyceridemia Induced by Bexarotene of Cutaneous T Cell Lymphoma (NCT01569724) | Rennes University Hospital | 2012-01-01 |
| Outcomes of Cutaneous T-Cell Lymphoma and Graft-Versus-Host Disease With Extracorporeal Photopheresis Treatment (NCT01460914) | Dartmouth-Hitchcock Medical Center | 2011-10-01 |
| Analysis of Cutaneous and Hematologic Disorders by High-Throughput Nucleic Acid Sequencing (NCT01556828) | Stanford University | 2011-06-01 |
| Low-dose (12 Gy) TSEBT+Vorinostat Versus Low-dose TSEBT Monotherapy in Mycosis Fungoides (NCT01187446) | Stanford University | 2010-12-01 |
| RAD001 Combined With CHOP in Newly Diagnosed Peripheral T-cell Lymphomas (NCT01198665) | Samsung Medical Center | 2010-07-01 |
| Open-label Pilot Study of Lenalidomide (Revlimid) as Adjuvant Treatment for Refractory Cutaneous T Cell Lymphoma (NCT01132989) | Florida Academic Dermatology Centers | 2010-05-01 |
| Ph II of Non-myeloablative Allogeneic Transplantation Using TLI & ATG In Patients w/ Cutaneous T Cell Lymphoma (NCT00896493) | Stanford University | 2009-05-01 |
| Recalcitrant Pruritus in Cutaneous T-Cell Lymphoma (NCT00863395) | University of Minnesota | 2008-12-01 |
| Tazarotene 0.1% Cream For the Treatment of Cutaneous T-Cell Lymphoma: A Prospective Study (NCT00779896) | McGill University | 2008-10-01 |
| A Study for Participants With Relapsed Cutaneous T-Cell Lymphoma (NCT00744991) | Eli Lilly and Company | 2008-09-01 |
| Study of Oral LBH589 in Patients With Cutaneous T-cell Lymphoma and Adult T-cell Leukemia/Lymphoma (NCT00699296) | Novartis Pharmaceuticals | 2008-05-01 |
| Study of Pralatrexate in Patients With Relapsed or Refractory Cutaneous T-cell Lymphoma (NCT00554827) | Acrotech Biopharma Inc. | 2007-08-01 |
| Study of Oral LBH589 in Adult Participants With Refractory/Resistant Cutaneous T-Cell Lymphoma (CTCL) (NCT00490776) | Novartis Pharmaceuticals | 2007-07-05 |
| Topical Romidepsin to Treat Early-Stage Cutaneous T-Cell Lymphoma (NCT01445340) | National Cancer Institute (NCI) | 2007-04-21 |
| A Study of APO866 for the Treatment of Cutaneous T-cell Lymphoma (NCT00431912) | Valerio Therapeutics | 2007-02-01 |
| Study of Oral LBH589 in Adult Patients With Refractory Cutaneous T-Cell Lymphoma (NCT00425555) | Novartis Pharmaceuticals | 2007-01-01 |
| LBH589 in Adult Patients With Advanced Solid Tumors or Cutaneous T-cell Lymphoma (NCT00412997) | Novartis | 2006-11-01 |
| A Phase II Clinical Trial of PXD101 in Patients With Recurrent or Refractory Cutaneous and Peripheral T-Cell Lymphomas (NCT00274651) | Valerio Therapeutics | 2006-01-01 |
| Effect of Denileukin Diftitox on Immune System in CTCL Patients (NCT00254332) | University of Pittsburgh | 2005-11-01 |
| Combination Drug Study of Bexarotene and Rosiglitazone to Treat CTCL (NCT00178841) | Vanderbilt University | 2005-06-01 |
| Oral SAHA (Suberoylanilide Hydroxamic Acid) in Advanced Cutaneous T-cell Lymphoma (0683-001) (NCT00091559) | Merck Sharp & Dohme LLC | 2005-02-03 |
| A Single Agent Phase II Study of Romidepsin (Depsipeptide, FK228) in the Treatment of Cutaneous T-cell Lymphoma (CTCL) (NCT00106431) | Celgene | 2005-01-01 |
| Blood, Urine, and Tissue Collection for Cutaneous Lymphoma, Eczema, and Atopic Dermatitis Research (NCT00177268) | University of Pittsburgh | 2004-10-01 |
| Immunization Against Tumor Cells in Sezary Syndrome (NCT00099593) | University of Pittsburgh | 2004-09-01 |
| Photopheresis as an Interventional Therapy for the Treatment of CTCL (Cutaneous T-Cell Lymphoma, Mycosis Fungoides) Stage 1A, 1B, 2A (NCT00221039) | M.D. Anderson Cancer Center | 2004-04-02 |
| Clinical Trial of HuMax-CD4, a New Drug to Treat Advanced Stage T-Cell Lymphoma in the Skin. (NCT00071084) | Genmab | 2003-05-27 |
| Clinical Trial of HuMax-CD4, a New Drug to Treat Early Stage T-Cell Lymphoma in the Skin. (NCT00071071) | Genmab | 2003-04-30 |
| In Vitro Evaluation of Immune Responses in Cutaneous T-Cell Lymphoma (CTCL) (NCT00177190) | University of Pittsburgh | 2002-06-01 |
| Study of Oral Bexarotene in Combination With Photopheresis for Treatment of Cutaneous T-Cell Lymphoma (NCT00306969) | Boston University | 2001-12-01 |
| Depsipeptide to Treat Patients With Cutaneous T-Cell Lymphoma and Peripheral T-Cell Lymphoma (NCT00007345) | National Cancer Institute (NCI) | 2001-03-08 |